NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The company is headquartered in Haifa, Haifa. The company went IPO on 2012-05-08. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The firm focuses on research and development of pharmaceutical technologies.
Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
Ingresos
0
0
0
0
0
0
Crecimiento de los Ingresos (YoY)
--
--
--
--
--
--
Costo de los ingresos
--
--
--
--
--
--
Utilidad bruta
--
--
--
--
--
--
Venta, General y Administración
3
1
0
0
1
1
Investigación y Desarrollo
2
0
0
0
0
0
Gastos de Operación
6
1
1
1
1
1
Otras Ingresos (Gastos) No Operativos
--
--
--
--
--
--
Ingreso antes de impuestos
-6
-1
-1
-1
-1
-1
Gasto por Impuesto a la Renta
--
--
--
--
--
--
Ingreso Neto
-6
-1
-1
-1
-1
-1
Crecimiento de la Utilidad Neta
20%
0%
0%
0%
0%
--
Acciones en Circulación (Diluidas)
91.02
91.02
87.29
77.58
76.03
73.6
Cambio de Acciones (YoY)
24%
24%
23%
22%
24%
30%
EPS (Diluido)
-0.07
-0.01
-0.01
-0.01
-0.02
-0.02
Crecimiento de EPS
-9%
-15%
-26%
-4%
13%
40%
Flujo de efectivo libre
-4
-1
-1
-1
-1
-1
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
--
--
--
--
--
--
Margen de operación
0%
0%
0%
0%
0%
0%
Margen de beneficio
0%
0%
0%
0%
0%
0%
Margen de flujo de caja libre
0%
0%
0%
0%
0%
0%
EBITDA
-6
-1
-1
-1
-1
-1
Margen de EBITDA
0%
0%
0%
0%
0%
0%
D&A para EBITDA
0
0
0
0
0
0
EBIT
-6
-1
-1
-1
-1
-1
Margen de EBIT
0%
0%
0%
0%
0%
0%
Tasa de Impuesto Efectiva
--
--
--
--
--
--
Follow-Up Questions
Nurexone Biologic Inc'in temel mali tabloları nelerdir?
Son mali tabloya (Form-10K) göre, Nurexone Biologic Inc'in toplam varlıkları $0 olup, net pérdida $0'dir.
NRXBF'ün temel finansal oranları nelerdir?
Nurexone Biologic Inc'in cari oranı 0, net kâr marjı 0, hisse başına satış $0'dir.
Nurexone Biologic Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?
El segmento de ingresos más grande es Nurexone Biologic Inc, con unos ingresos de On-site Services - Connectivity en el último informe de ganancias. En cuanto a la geografía, France es el mercado principal para Nurexone Biologic Inc, con unos ingresos de 403,300,000.
Nurexone Biologic Inc kârlı mı?
no, son mali tablolara göre Nurexone Biologic Inc'in net pérdida $0'dir.
Nurexone Biologic Inc'in herhangi bir yükümlülüğü var mı?
no, Nurexone Biologic Inc'in yükümlülüğü 0'dir.
Nurexone Biologic Inc'in tedavüldeki hisse sayısı kaçtır?
Nurexone Biologic Inc'in toplam tedavüldeki hisse sayısı 0'dir.